Quantification of Cells Expressing Mesenchymal Stem Cell Markers in Healthy and Osteoarthritic Synovial Membranes

Hermida‐Gómez, Tamara; Fuentes‐Boquete, Isaac; Gimeno-Longas, Maria José; Muiños‐López, Emma; Díaz‐Prado, Silvia; Toro, Javier de; Blanco, Francisco J.

doi:10.3899/jrheum.100614

Cited by 84 publications

(72 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results from flow cytometric analysis and immunofluorescence correspond with other studies (Hermida-Gomez et al 2011) which found that SFMSCs are negative for hematopoietic markers (CD34 and CD45) and positive for mesenchymal markers (CD44, CD73, CD90, CD105, and CD106; Figure 2). Molecular characterization showed that stem cell marker expressions varied among the three cell lines.…”

Section: Discussionsupporting

confidence: 91%

Therapeutic potential of autologous mesenchymal stem cells derived from synovial fluid in patients with degenerative arthritis

Chang

Park

Jun

et al. 2013

Animal Cells and Systems

View full text Add to dashboard Cite

(2013) Therapeutic potential of autologous mesenchymal stem cells derived from synovial fluid in patients with degenerative arthritis, Animal Cells and Systems, 17:5, 315-324, DOI: 10.1080/19768354.2013.832705 To link to this article: https://doi.org/10. 1080/19768354.2013 The possibility to isolate synovial fluid-derived mesenchymal stem cells (SFMSCs) from patients with degenerative arthropathy has been an interest since synovial fluid (SF) from osteoarthritis (OA) patients offered a unique stem-cell resource for therapeutic applications. In this study, we successfully isolated, cytogenetically and molecularly characterized, and followed the differentiation potency of human mesenchymal stem cells (MSCs) from SF. The morphology of proliferating SFMSCs showed fibroblast-like morphology, and both the population doubling time (DT) and viability of MSCs from bone marrow, adipose, and SF did not differ. The immunophenotype of SFMSCs was confirmed by the positive expression of CD44, CD73, CD90, CD105, and CD106 by flow cytometry and immunocytochemistry, and the expression of the hematopoietic markers, CD34 and CD45, was not found. In all MSCs from three different origins, we measured the mRNA expression of developmentally important transcript factors such as KLF4, c-Myc, Sox2, and OCT4. SFMSCs from OA patients showed normal chromosomal number, structure, and telomerase activity. SFMSCs showed multipotent capacity, and was differentiated into neurocyte, adipocyte, osteocyte, and chondrocyte in vitro, as demonstrated by specific stains and expression of molecular markers. In addition, SFMSCs also have the capacity to secrete immunomodulating factors (IL-4, IL-10, IL-13, and transforming growth factor-b (TGF-b)) involved in the therapy of rheumatoid arthritis (RA). These results demonstrate that SFMSCs from OA-patients might provide therapeutic options for RA and OA.

show abstract

Section: Discussionsupporting

confidence: 91%

Therapeutic potential of autologous mesenchymal stem cells derived from synovial fluid in patients with degenerative arthritis

Chang

Park

Jun

et al. 2013

Animal Cells and Systems

View full text Add to dashboard Cite

show abstract

“…Unwanted differentiation is also unlikely when MSC are injected as a suspension of single cells in a large fluid-filled space where they are also naturally present in healthy individuals without causing such problems [7]. In a damaged osteoarthritic (OA) joint the number of MSC in synovial tissue and synovial fluid is significantly higher than in healthy or rheumatic joint, nevertheless no cartilage or bone formation in such a damaged joint occurs [55,8,7]. Many research groups have investigated whether one can obtain cartilage formation by injecting a suspension of MSC in a joint in OA.…”

Section: Transdifferentiation and Engraftmentmentioning

confidence: 98%

Mesenchymal stromal cells for treatment of arthritis

Swart

Wulffraat

2014

Best Practice & Research Clinical Rheumatology

View full text Add to dashboard Cite

“…5 Joint-derived stem cells, including infrapatellar fat pad (fat pad-derived stem cells [FPSCs]) and synovial membrane-derived stem cells (SDSCs) are a promising alternative cell source for cartilage repair therapies that may overcome many of the problems associated with the use of primary CCs. [6][7][8][9][10][11] When compared to mesenchymal stem cells (MSCs) derived from other tissues, joint tissue-derived stem cells have demonstrated superior capacity for chondrogenesis. 12,13 This has led to increased interest in the field of regenerative medicine to develop novel stem cell-based therapies using SDSCs for the treatment of damaged and diseased cartilage.…”

Section: Introductionmentioning

confidence: 99%

A Comparison of the Functionality andIn VivoPhenotypic Stability of Cartilaginous Tissues Engineered from Different Stem Cell Sources

Vinardell

Sheehy

Buckley

et al. 2012

Tissue Engineering Part A

153

136

View full text Add to dashboard Cite

Quantification of Cells Expressing Mesenchymal Stem Cell Markers in Healthy and Osteoarthritic Synovial Membranes

Abstract: Synovial membranes from patients with OA contain more cells positive for CD44, CD90, and CD105 antigens than those from joints with undamaged cartilage.

Cited by 84 publications

References 21 publications

Therapeutic potential of autologous mesenchymal stem cells derived from synovial fluid in patients with degenerative arthritis

Therapeutic potential of autologous mesenchymal stem cells derived from synovial fluid in patients with degenerative arthritis

Mesenchymal stromal cells for treatment of arthritis

A Comparison of the Functionality andIn VivoPhenotypic Stability of Cartilaginous Tissues Engineered from Different Stem Cell Sources

Contact Info

Product

Resources

About